NXTC
$12.32
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
Recent News
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Companies Like NextCure (NASDAQ:NXTC) Could Be Quite Risky
We can readily understand why investors are attracted to unprofitable companies. For example, although...
NextCure and Simcere partner to develop SIM0505 for solid tumours
The SIM0505 employs a unique epitope which enhances tumour binding.
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients […]